Basic Information
J05AF13
tenofovir alafenamide
Antivirals for systemic use
Therapeutic indication
Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).
Overview Summary
This is a summary of the European public assessment report (EPAR) for Vemlidy. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vemlidy.
For practical information about using Vemlidy, patients should read the package leaflet or contact their doctor or pharmacist.
Active Substances (2)
tenofovir alafenamide fumarate
tenofovir alafenamide fumarate
Documents (13)
Vemlidy : EPAR - Summary for the public
March 9, 2017
OVERVIEW_DOCUMENT
CHMP summary of positive opinion for Vemlidy
November 10, 2016
INITIAL_MARKETING_AUTHORISATION_DOCUMENTS
Vemlidy : EPAR - Public assessment report
March 9, 2017
INITIAL_MARKETING_AUTHORISATION_DOCUMENTS
Vemlidy-H-C-004169-II-0040 : EPAR - Assessment report - Variation
May 31, 2023
CHANGES_SINCE_INITIAL_AUTHORISATION
Vemlidy : EPAR - All Authorised presentations
March 9, 2017
AUTHORISED_PRESENTATIONS
Vemlidy : EPAR - Public assessment report
March 9, 2017
CHANGES_SINCE_INITIAL_AUTHORISATION
CHMP summary of positive opinion for Vemlidy
November 10, 2016
CHANGES_SINCE_INITIAL_AUTHORISATION
Vemlidy : EPAR - Risk management plan
August 18, 2021
RISK_MANAGEMENT_PLAN_SUMMARY
CHMP post-authorisation summary of positive opinion for Vemlidy (II-40)
April 26, 2023
CHANGES_SINCE_INITIAL_AUTHORISATION
Vemlidy : EPAR - Procedural steps taken and scientific information after authorisation
December 19, 2017
CHANGES_SINCE_INITIAL_AUTHORISATION
Vemlidy : EPAR - Product Information
March 9, 2017
DRUG_PRODUCT_INFORMATION
Vemlidy-H-C-PSUSA-00010575-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
September 5, 2022
CHANGES_SINCE_INITIAL_AUTHORISATION
Vemlidy-H-C-PSUSA-00010575-201911 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(
September 14, 2020
CHANGES_SINCE_INITIAL_AUTHORISATION
Overview Q&A (8)
Question
What are the risks associated with Vemlidy?
Answer
The most common side effects with Vemlidy are headache (11% of patients), nausea (6% of patients) and tiredness (6% of patients). For the full list of side effects and restrictions see the package leaflet.
Question
How is Vemlidy used?
Answer
Vemlidy is available as 25 mg tablets which are taken by mouth (one tablet a day) with food.The patient will usually take their medicine for at least 6 to 12 months, and treatment may last several years.
Vemlidy can only be obtained with a prescription.
Question
How does Vemlidy work?
Answer
The active substance in Vemlidy, tenofovir alafenamide, works by stopping the hepatitis B virus in the liver from multiplying. It is converted in the body into its active compound tenofovir, which blocks the activity of reverse transcriptase, an enzyme made by the hepatitis B virus that allows it to reproduce itself in the cells it has infected.
Question
What benefits of Vemlidy have been shown in studies?
Answer
Vemlidy reduces levels of hepatitis B virus in most patients. In a study of 426 patients with ‘e-antigen negative’ chronic hepatitis, 94% of patients on Vemlidy had very low levels of viral DNA after 48 weeks of treatment. This result was similar to that in patients taking another form of tenofovir (tenofovir disoproxil fumarate) where 93% had very low viral DNA levels.
In a second study of 875 patients with ‘e-antigen positive’ chronic hepatitis, 64% of patients taking Vemlidy and 67% of those taking tenofovir disoproxil fumarate had very low levels of viral DNA after 48 weeks. These results suggest that the comparator medicine might be more effective in ‘e-antigen positive’ cases but differences seen are small.
The terms ‘e-antigen positive’ and ‘e-antigen negative’ refer to the presence or absence of e-antigen, a hepatitis B viral protein. If this protein is present, it means that the virus is multiplying rapidly and the viral load may be higher.
Question
What measures are being taken to ensure the safe and effective use of Vemlidy?
Answer
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vemlidy have been included in the summary of product characteristics and the package leaflet.
Question
Other information about Vemlidy
Answer
The European Commission granted a marketing authorisation valid throughout the European Union for Vemlidy on 9 January 2017.
For more information about treatment with Vemlidy, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Question
What is Vemlidy and what is it used for?
Answer
Vemlidy is an antiviral medicine for treating chronic (long-term) hepatitis B, an infectious disease that affects the liver.
This medicine is used in patients aged 12 years and older weighing at least 35 kg. It contains the active substance tenofovir alafenamide.
Question
Why is Vemlidy approved?
Answer
Vemlidy suppresses levels of hepatitis B virus in the body, and its effectiveness is comparable to that of another tenofovir medicine (tenofovir disoproxil fumarate). With regard to its risks, the side effects of Vemlidy are manageable. In addition, Vemlidy is effective at a lower dose than tenofovir disoproxil fumarate and may lead to reduced side effects in the kidneys and bones.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that the benefits of Vemlidy outweigh its risks and recommended its approval in the EU.